scholarly journals PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer

Oncotarget ◽  
2017 ◽  
Vol 8 (35) ◽  
pp. 58457-58468 ◽  
Author(s):  
Cuiling Zhou ◽  
Jianjun Tang ◽  
Huanhuan Sun ◽  
Xiaobin Zheng ◽  
Zhanyu Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Poor Prognostic Factor

scholarly journals PICT1 expression is a poor prognostic factor in non-small cell lung cancer

Oncoscience ◽  
2014 ◽  
Vol 1 (5) ◽  
pp. 375-382 ◽  
Author(s):  
Kyoko Okamura ◽  
Koichi Takayama ◽  
Kohichi Kawahara ◽  
Taishi Harada ◽  
Miki Nishio ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Poor Prognostic Factor

scholarly journals Sarcopenia is a novel poor prognostic factor in male patients with pathological Stage I non-small cell lung cancer

2017 ◽  
Vol 47 (4) ◽  
pp. 363-368 ◽  
Author(s):  
Takuma Tsukioka ◽  
Noritoshi Nishiyama ◽  
Nobuhiro Izumi ◽  
Shinjiro Mizuguchi ◽  
Hiroaki Komatsu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Pathological Stage ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Male Patients

Loss of PTEN Expression is an Independent Poor Prognostic Factor in Non-small Cell Lung Cancer

2011 ◽  
Vol 45 (4) ◽  
pp. 329 ◽  
Author(s):  
Seol Bong Yoo ◽  
Xianhua Xu ◽  
Hyun Ju Lee ◽  
Sanghoon Jheon ◽  
Choon-Taek Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Pten Expression ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor

High expression of ERCC1 is a poor prognostic factor in Chinese patients with non-small cell lung cancer receiving cisplatin-based therapy

2010 ◽  
Vol 22 (4) ◽  
pp. 296-302 ◽  
Author(s):  
Qing-zhi Guo ◽  
Jie Wang ◽  
Hua Bai ◽  
Tong-tong An ◽  
Meina Wu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Expression ◽  
Chinese Patients ◽  
Small Cell Lung ◽  
Poor Prognostic Factor

Overexpression of FADD and Bcl-XS proteins as novel prognostic biomarkers for surgically resected non-small cell lung cancer

2020 ◽  
pp. 1-10
Author(s):  
Lingjiao Chen ◽  
Guiyuan Xie ◽  
Juan Feng ◽  
Qiuyuan Wen ◽  
Hongjing Zang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Independent Poor Prognostic Factor ◽  
Elevated Expression

BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most widespread cancer with increasing morbidity and mortality. FAS-associated protein with death domain (FADD) is considered as an essential instrument in cell death, whereas Bcl-XS promotes apoptosis through inhibiting the activity of Bcl-2 and Bcl-XL. OBJECTIVE AND METHODS: We detected the expression of FADD and Bcl-XS in resected NSCLC tissues by immunohistochemistry, and investigated their association with clinicopathological characteristics and prognostic significance of NSCLC patients. RESULTS: Bcl-XS expression was significantly increased in well and moderate differentiated lung SCC (P= 0.004). Lung ADC patients with overexpression of FADD and lung SCC patients with low expression of Bcl-XS had importantly lower overall survival rates by Kaplan-Meier analysis (P= 0.033, P= 0.02, respectively). Multivariate analysis confirmed that elevated expression of FADD was an independent poor prognostic factor for patients with surgically resected lung ADC (P= 0.027) and increased expression of Bcl-XS was an independent good prognostic factor for patients with surgically resected lung SCC (P= 0.016) CONCLUSION: Elevated expression of FADD was identified as independent poor prognostic factor for patients with surgically resected lung ADC, however, increased expression of Bcl-XS was an independent good prognostic biomarker for patients with surgically resected lung SCC.

High Expression of Integrin ??1 and p53 is a Greater Poor Prognostic Factor Than Clinical Stage in Small-Cell Lung Cancer

2004 ◽  
Vol 27 (3) ◽  
pp. 215-219 ◽  
Author(s):  
Fumihiro Oshita ◽  
Yoichi Kameda ◽  
Nobuyuki Hamanaka ◽  
Haruhiro Saito ◽  
Kouzo Yamada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
High Expression ◽  
Small Cell Lung ◽  
Poor Prognostic Factor

Stage IA non-small cell lung cancer: Vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy

Lung Cancer ◽  
2007 ◽  
Vol 56 (3) ◽  
pp. 341-348 ◽  
Author(s):  
Tomoshi Tsuchiya ◽  
Shinji Akamine ◽  
Masashi Muraoka ◽  
Ryotaro Kamohara ◽  
Koichi Tsuji ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Vessel Invasion ◽  
Stage Ia

Evaluation of Two Phosphorylation Sites Improves the Prognostic Significance of Akt Activation in Non–Small-Cell Lung Cancer Tumors

2006 ◽  
Vol 24 (2) ◽  
pp. 306-314 ◽  
Author(s):  
Junji Tsurutani ◽  
Junya Fukuoka ◽  
Hiroko Tsurutani ◽  
Joanna H. Shih ◽  
Stephen M. Hewitt ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Surrounding Tissue ◽  
Small Cell Lung ◽  
Poor Prognostic Factor ◽  
Akt Activation

Purpose Akt is a serine/threonine kinase that has been implicated in lung tumorigenesis and lung cancer therapeutic resistance. Full activation of Akt requires two phosphorylation events, but only one site of phosphorylation (S473) has been evaluated thus far in clinical non–small-cell lung cancer (NSCLC) specimens, which has resulted in conflicting results regarding the prognostic significance of Akt activation in NSCLC. In this study, we sought to determine whether evaluation of Akt phosphorylation at T308 would improve prognostic accuracy. Patients and Methods Phosphospecific antibodies against T308 and S473 were validated and used in an immunohistochemical analysis of tissue microarray slides containing NSCLC specimens (n = 300) and surrounding lung tissue specimens (n = 100). Results Phosphorylation of either S473 or T308 was positive in most NSCSLC specimens, but was detected rarely in surrounding normal tissues. When Akt activation was defined by using both sites of phosphorylation, Akt activation was specific for NSCLC tumors versus surrounding tissue (73.4% v 0%; P < .05), was higher in adenocarcinoma than in squamous cell carcinoma (78.1% v 68.5%; P = .040), and was associated with shorter overall survival for all stages of disease (log-rank P = .041). In multivariate analyses, increased phosphorylation of T308 alone was a poor prognostic factor for stage I patients or for tumors < 5 cm (log-rank P = .011 and P = .015, respectively). Conclusion These results suggest that monitoring phosphorylation of Akt at T308 improves the assessment of Akt activation, and show that Akt activation is a poor prognostic factor for all stages of NSCLC.

scholarly journals Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer

2021 ◽  
Author(s):  
Amila Suraweera ◽  
Alex Duff ◽  
Mark N. Adams ◽  
Christian Jekimovs ◽  
Pascal H. G. Duijf ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Therapeutic Target ◽  
Small Cell ◽  
Small Cell Lung ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document